Charles River Laboratories (CRL) Tops Q2 EPS by 23c; Raises Guidance

Charles River Laboratories (NYSE: CRL) reported Q2 EPS of $2.61, $0.23 better than the analyst estimate of $2.38. Revenue for the quarter came in at $914.6 million versus the consensus estimate of $880.65 million.

James C. Foster, Chairman, President and Chief Executive Officer, said, “The strength of our leading, non-clinical contract research and manufacturing portfolio was clearly demonstrated in our second-quarter financial performance. Robust industry fundamentals continue to drive unprecedented client demand across most of our businesses, and we are extremely well positioned to succeed in this environment.”

“Due to the sustained demand, we are intensely focused on the execution of our strategy, including strengthening our portfolio and strategically adding staff and capacity to support our clients and provide exceptional service to them. We believe the success of this strategy will enable us to achieve our increased 2021 financial guidance, as well as our longer-term strategic and financial goals,” Mr. Foster concluded.

GUIDANCE:

Charles River Laboratories sees FY2021 EPS of $10.10-$10.35, versus prior of $9.75-$10.00 and the consensus of $9.95. Sees Revenue growth of 20.5-22% versus prior of 19-21%.

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.

You May Also Be Interested In

• Tesla touts acceleration of new models, but Q1 results fall short of estimates
• Visa (V) Tops Q2 EPS by 7c, offers guidance
• Mattel (MAT) Tops Q1 EPS by 7c, Revenue Misses, Offers Guidance